Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
5 hedge funds and large institutions have $11.1M invested in Plus Therapeutics in 2014 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
73% less capital invested
Capital invested by funds: $41.4M → $11.1M (-$30.3M)
91% less call options, than puts
Call options by funds: $8K | Put options by funds: $85K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Goldman Capital Management
New York
|
+$4.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$151K |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$51K |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$35K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$27K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TC
76
TFS Capital
West Chester,
Pennsylvania
| – | -$51K | – | – |
|
|
77
Tudor Investment Corp
Stamford,
Connecticut
| – | -$35K | – | – |
|
|
VFA
78
Virtus Fund Advisers
Hartford,
Connecticut
| – | -$14K | – | – |
|
PSTV Hedge Fund Activity: Q3 2014 in Review
5 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q3 2014, worth a combined $11.1M — down 73% from $41.4M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PSTV positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Goldman Capital Management, opening a new position worth an estimated $4.54M. The largest seller was Rotella Capital Management, cutting an estimated $151K.
- 5 institutional investors held Plus Therapeutics (PSTV) as of Q3 2014, up from 4 in Q2 2014.
- Funds reported $11.1M of Plus Therapeutics stock for Q3 2014, down 73% quarter-over-quarter.
- 1 fund opened new Plus Therapeutics positions in Q3 2014 and 0 closed out, a net change of +1 holder.
- The largest Plus Therapeutics buyer in Q3 2014 was Goldman Capital Management, an estimated $4.54M added.
- The largest Plus Therapeutics seller in Q3 2014 was Rotella Capital Management, an estimated $151K sold.
Based on aggregated 13F filings for Q3 2014.